Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd ...
Intratumoral injections of INT230-6 were well tolerated with no drug-related serious adverse events or dose-limiting toxicity in Phase 1/2 clinical study Preclinical research demonstrates drug dispersion benefit of DfuseRxSM technology WESTPORT, Conn., …